Covid-19

Symbiotics statement on the Coronavirus (COVID-19) epidemic

March 19, 2020

Geneva, March 18, 2020

Dear Clients and Partners,

We would like to update you on Symbiotics’ response to the pandemic situation and public health policies being put in place in our various markets and locations.

Our priority is to reduce the risk of infection of our clients, partners and staff, and their families, as well as sparing the congestion of our health systems and the higher risk incurred by more vulnerable population.

We have thus gradually been implementing over the past weeks a travel- ban and work-at-home policy, which is currently in place for all staff across the firm. We have been testing all remote and virtual work media, in parallel to implementing our business continuity plan, and can confirm that the firm is up and running and fully operational. Digital security has in addition been reinforced for each workstation. We do not expect any material change in our client service and delivery.

All business continuity measures will remain in force until local authorities in each of our locations respectively lift their exceptional public health policies. If you have any questions, please contact the relevant persons you normally interact with at Symbiotics.

We are also monitoring each and every single one of our target investor and investee markets, and their macroeconomic developments, with a particular focus on interest rate and currency dynamics, through our various locations and risk management systems, updating our teams regularly and advising our clients and partners accordingly, on their current books or contemplated deal-flow. We are closing the first quarter with a normal to slightly higher than usual business activity, and at this stage are not seeing any material changes in our overall deal- flow in the coming quarter.

We remain fully committed to providing you with the best service and support possible. Most importantly we hope that you and your loved ones are healthy during this period.

Yours sincerely,
Symbiotics
PDF